Cargando…
Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
Background: Numerous driver mutations have been identified in colorectal cancer (CRC), but their relevance to the development of targeted therapies remains elusive. The secondary effects of pathogenic driver mutations on downstream signaling pathways offer a potential approach for the identification...
Autores principales: | Menyhart, Otília, Kakisaka, Tatsuhiko, Pongor, Lőrinc Sándor, Uetake, Hiroyuki, Goel, Ajay, Győrffy, Balázs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679198/ https://www.ncbi.nlm.nih.gov/pubmed/31337155 http://dx.doi.org/10.3390/cancers11070983 |
Ejemplares similares
-
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
por: Menyhárt, Otília, et al.
Publicado: (2019) -
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
por: Nagy, Ádám, et al.
Publicado: (2016) -
A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years
por: Ősz, Ágnes, et al.
Publicado: (2017) -
Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019) -
Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
por: Menyhárt, Otília, et al.
Publicado: (2020)